John C. Byrd , MD

Bachelor of Arts: Hendrix College Conway, Arkansas, 1987 (Chemistry)

Doctor of Medicine: University of Arkansas Little Rock, Arkansas, 1991

Residency: Walter Reed Army Medical Center Washington, DC, 1994 (Internal Medicine)

Fellowship: Walter Reed Army Medical Center Washington, DC, 1996 (Hematology, Oncology, Bone Marrow Transplantation)

American Board of Internal Medicine (Hematology) (Certification Date: 11-14-2007 ) - (Recertification Date: to 05-19-2024 )

Hematology and Oncology

Leukemia

Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Myelodysplastic Syndrome

Hematology

Internal Medicine

Medical Oncology

Grant: #UG1CA233338 07-01-2021 -02-28-2022 National Cancer Institute ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies Role:PI 1469675.45 Hold Level:Federal

Grant: #UG1CA233338 07-01-2021 -02-28-2022 National Cancer Institute ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies Role:PI 1469675.45 Hold Level:Federal

Grant: #R35CA197734 Investigators:Byrd, John; Scaglioni, Pier Paolo 07-01-2021 -08-31-2022 National Cancer Institute Targeted Therapy for Leukemia Role:PI 170582.23 Hold Level:Federal

Grant: #K99CA246083 (Actual PI: Fellow Abdul-Aziz, Amina) Investigators:Abdul-Aziz, Amina; Byrd, John; Scaglioni, Pier Paolo 09-01-2021 -01-31-2022 National Cancer Institute Impact of the senescent bone marrow microenvironment in AML biology Role:PI 76161.00 Awarded Level:Federal

Grant: #Alliance for Clinical Trials in Oncology Investigators:Byrd, John 02-01-2022 -01-31-2029 Brigham and Women's Hospital, Inc. Alliance for Clinical Trials in Oncology Role:PI 0.00 Hold Level:Non Profit

Grant: #R01CA213442 07-01-2021 -02-28-2022 National Cancer Institute Unlocking the Potential of PI3K Inhibition in CLL Role:PI 84130.60 Hold Level:Federal

Grant: #R01CA213442 07-01-2021 -02-28-2022 National Cancer Institute Unlocking the Potential of PI3K Inhibition in CLL Role:PI 84130.60 Hold Level:Federal

Grant: #NX-2127-001 Investigators:Byrd, John 12-01-2021 -12-01-2024 Precision for Medicine A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies Role:PI 308602.66 Hold Level:Industry

Grant: #IOV-CLL-01 09-01-2021 -09-01-2024 Iovance Biotherapeutics, Inc. A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Role:PI 0.00 Hold Level:Industry

Grant: #IOV-CLL-01 09-01-2021 -09-01-2024 Iovance Biotherapeutics, Inc. A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Role:PI 0.00 Hold Level:Industry

Grant: #TL-895-209 04-01-2022 -03-31-2025 Telios Pharma, Inc An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naive Myelofibrosis (MF) Subjects Role:PI 241305.26 Hold Level:Industry

Grant: #TL-895-209 04-01-2022 -03-31-2025 Telios Pharma, Inc An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naive Myelofibrosis (MF) Subjects Role:PI 241305.26 Hold Level:Industry

Grant: #CA097-001 04-01-2022 -03-31-2025 Bristol-Myers Squibb Co. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF BMS-986403 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) Role:PI 970213.50 Hold Level:Industry

Grant: #CA097-001 04-01-2022 -03-31-2025 Bristol-Myers Squibb Co. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF BMS-986403 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) Role:PI 970213.50 Hold Level:Industry

Grant: #SNDX-5613-0700 02-07-2023 -01-28-2028 ICON Clinical Research, LLC A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement Role:PI 0.00 Active Level:Industry

Grant: #SNDX-5613-0700 02-07-2023 -01-28-2028 ICON Clinical Research, LLC A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement Role:PI 0.00 Active Level:Industry

Grant: #ONO-7018-01 Investigators:Byrd, John 05-17-2023 -05-19-2026 Ono Pharmaceutical Co., Ltd. A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 Role:PI 0.00 Hold Level:Industry

Grant: #NX-5948-301 Investigators:Byrd, John 08-24-2023 -09-13-2026 Nurix A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies Role:PI 562050.47 Hold Level:Industry

Grant: #OSU; SPC-1000012463 / GR132979/ R01HL170038 Investigators:Byrd, John 08-05-2023 -04-30-2024 National Heart, Lung and Blood Institute Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity Role:PI 18744.00 Hold Level:Federal

Grant: #Alliance NCTN CSA Investigators:Byrd, John 08-01-2020 -07-31-2027 National Cancer Institute Alliance NCTN Foundation (ANF) Role:PI 1000.00 Hold Level:Federal

Grant: #CA230759 Investigators:Byrd, John; Hertlein, Erin 09-30-2024 -09-29-2027 Department of the Army Medical Research Acquisition Activity Plasmacytoid dendritic cells (pDCs) as a Primary Node of Immune Suppression and Treatment Resistance in Acute Myeloid Leukemia Role:Collaborator 1561794.00 Hold Level:Federal

Grant: #CA097-001 Investigators:Byrd, John 03-29-2024 -04-25-2024 Bristol-Myers Squibb Co. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF BMS-986403 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) Role:PI 17900.00 Hold Level:Industry

Grant: #2024 Research Award Grant Investigators:Byrd, John 07-01-2024 -06-30-2026 CLL Society Understanding and Targeting Clonal Hematopoiesis in Chronic Lymphocytic Leukemia - CLL Role:PI 200000.00 Hold Level:Non Profit

Grant: #M23-647 Investigators:Byrd, John 08-26-2024 -08-26-2027 AbbVie, Inc. First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies Role:PI 1288272.54 Hold Level:Industry

Grant: #CC-99282-CLL-001 Investigators:Byrd, John 10-16-2024 -10-16-2027 Celgene Corporation Cancellation reimbursement for CC-99282-CLL-001 Role:PI 0.00 Hold Level:Industry

Grant: #KRT-232-115 Investigators:Byrd, John 11-11-2024 -11-11-2027 Kartos Therapeutics, Inc Phase 3, Rand, Dbl-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Roxolitinib in JAK Inhibitor-Naive Pts with Myelofibrosis Who have Suboptimal Role:PI 362528.58 Hold Level:Industry

Investigators:Byrd, John 11-22-2024 -11-22-2027 Ajax Therapeutics A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Th Role:PI 971449.90 Hold Level:Industry

Grant: #R01CA292084 04-01-2025 -03-31-2030 National Cancer Institute Pharmacodynamically directed targeted therapy for leukemia Role:PI 0.00 Hold Level:Federal

Grant: #R01CA292084 04-01-2025 -03-31-2030 National Cancer Institute Pharmacodynamically directed targeted therapy for leukemia Role:PI 0.00 Hold Level:Federal

Grant: #UB-VV111-01 Investigators:Byrd, John 04-30-2025 -04-30-2028 Umoja Biopharma, Inc. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF UB-VV111 IN COMBINATION WITH RAPAMYCIN IN RELAPSED OR REFRACTORY (R/R) CD19+ B-CELL MALIGNANCIES Role:PI 860418.07 Hold Level:Industry

Peer Reviewed Publications

Larkin, Karilyn T M; Byrd, John C (2021. ) Whole-genome sequencing for myeloid disease: one assay to stratify them all?.Nature reviews. Clinical oncology, , More Information

O'Brien, Susan M; Brown, Jennifer R; Byrd, John C; Furman, Richard R; Ghia, Paolo; Sharman, Jeff P; Wierda, William G (2021. ) Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.Frontiers in oncology, , 11 ,720704 More Information

Eisenmann, Eric D; Fu, Qiang; Muhowski, Elizabeth M; Jin, Yan; Uddin, Muhammad Erfan; Garrison, Dominique A; Weber, Robert H; Woyach, Jennifer; Byrd, John C; Sparreboom, Alex; Baker, Sharyn D (2021. ) Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.Cancer research communications, , 1 (2 ) ,79-89 More Information

Bhatnagar, Bhavana; Kohlschmidt, Jessica; Mrózek, Krzysztof; Zhao, Qiuhong; Fisher, James L; Nicolet, Deedra; Walker, Christopher J; Mims, Alice S; Oakes, Christopher; Giacopelli, Brian; Orwick, Shelley; Boateng, Isaiah; Blachly, James S; Maharry, Sophia E; Carroll, Andrew J; Powell, Bayard L; Kolitz, Jonathan E; Stone, Richard M; Byrd, John C; Paskett, Electra D; de la Chapelle, Albert; Garzon, Ramiro; Eisfeld, Ann-Kathrin (2021. ) Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.Cancer discovery, , 11 (3 ) ,626-637 More Information

Kittai, Adam S; Miller, Cecelia; Goldstein, Daniel; Huang, Ying; Abruzzo, Lynne V; Beckwith, Kyle; Bhat, Seema A; Bond, David A; Grever, Michael R; Heerema, Nyla A; Rogers, Kerry A; Ruppert, Amy S; Byrd, John C; Woyach, Jennifer A (2021. ) The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.Blood, , 138 (23 ) ,2372-2382 More Information

Walker, Alison R; Byrd, John C; Blachly, James S; Bhatnagar, Bhavana; Mims, Alice S; Orwick, Shelley; Lin, Tara L; Crosswell, Howland E; Zhang, Danjie; Minden, Mark D; Munugalavadla, Veerendra; Long, Lauren; Liu, Jinfeng; Pan, Yang; Oellerich, Thomas; Serve, Hubert; Rao, Arati V; Blum, William G (2020. ) Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression.Clinical cancer research : an official journal of the American Association for Cancer Research, , 26 (22 ) ,5852-5859 More Information

Rosko, Ashley E; Huang, Ying; Benson, Don M; Efebera, Yvonne A; Hofmeister, Craig; Jaglowski, Samantha; Devine, Steven; Bhatt, Geetika; Wildes, Tanya M; Dyko, Alanna; Jones, Desirée; Naughton, Michelle J; Byrd, John C; Burd, Christin E (2019. ) Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.Journal of geriatric oncology, , 10 (3 ) ,479-485 More Information

Greene, J T; Mani, Rajeswaran; Ramaswamy, Rahul; Frissora, Frank; Yano, Max; Zapolnik, Kevan; Harrington, Bonnie; Wasmuth, Ronni; Tran, Minh; Mo, Xiaokui; McKenna, Mary; Rangnekar, Vivek M; Byrd, John C; Bondada, Subbarao; Muthusamy, Natarajan (2019. ) Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.Blood advances, , 3 (8 ) ,1255-1266 More Information

Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A; Zhao, Weiqiang; Booth, Allison M; Ding, Wei; Bartlett, Nancy L; Brander, Danielle M; Barr, Paul M; Rogers, Kerry A; Parikh, Sameer A; Coutre, Steven; Hurria, Arti; Brown, Jennifer R; Lozanski, Gerard; Blachly, James S; Ozer, Hatice G; Major-Elechi, Brittny; Fruth, Briant; Nattam, Sreenivasa; Larson, Richard A; Erba, Harry; Litzow, Mark; Owen, Carolyn; Kuzma, Charles; Abramson, Jeremy S; Little, Richard F; Smith, Scott E; Stone, Richard M; Mandrekar, Sumithra J; Byrd, John C (2018. ) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.The New England journal of medicine, , 379 (26 ) ,2517-2528 More Information

Reiff, Sean D; Mantel, Rose; Smith, Lisa L; Greene, J T; Muhowski, Elizabeth M; Fabian, Catherine A; Goettl, Virginia M; Tran, Minh; Harrington, Bonnie K; Rogers, Kerry A; Awan, Farrukh T; Maddocks, Kami; Andritsos, Leslie; Lehman, Amy M; Sampath, Deepa; Lapalombella, Rosa; Eathiraj, Sudharshan; Abbadessa, Giovanni; Schwartz, Brian; Johnson, Amy J; Byrd, John C; Woyach, Jennifer A (2018. ) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.Cancer discovery, , 8 (10 ) ,1300-1315 More Information

Korman, Abraham M; Hastings, Justin G; Byrd, John C; Kaffenberger, Benjamin H (2017. ) Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia.JAMA dermatology, , 153 (1 ) ,108-110 More Information

Flinn, Ian W; Ruppert, Amy S; Harwin, William; Waterhouse, David; Papish, Steven; Jones, Jeffrey A; Hainsworth, John; Byrd, John C (2016. ) A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.American journal of hematology, , 91 (10 ) ,1020-5 More Information

Horwitz, Steven M; Zelenetz, Andrew D; Gordon, Leo I; Wierda, William G; Abramson, Jeremy S; Advani, Ranjana H; Andreadis, C Babis; Bartlett, Nancy; Byrd, John C; Fayad, Luis E; Fisher, Richard I; Glenn, Martha J; Habermann, Thomas M; Lee Harris, Nancy; Hernandez-Ilizaliturri, Francisco; Hoppe, Richard T; Kaminski, Mark S; Kelsey, Christopher R; Kim, Youn H; Krivacic, Susan; LaCasce, Ann S; Lunning, Matthew; Nademanee, Auayporn; Press, Oliver; Rabinovitch, Rachel; Reddy, Nishitha; Reid, Erin; Roberts, Kenneth; Saad, Ayman A; Sokol, Lubomir; Swinnen, Lode J; Vose, Julie M; Yahalom, Joachim; Zafar, Nadeem; Dwyer, Mary; Sundar, Hema; Porcu, Pierluigi (2016. ) NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.Journal of the National Comprehensive Cancer Network : JNCCN, , 14 (9 ) ,1067-79 More Information

Harrington, Bonnie K; Gardner, Heather L; Izumi, Raquel; Hamdy, Ahmed; Rothbaum, Wayne; Coombes, Kevin R; Covey, Todd; Kaptein, Allard; Gulrajani, Michael; Van Lith, Bart; Krejsa, Cecile; Coss, Christopher C; Russell, Duncan S; Zhang, Xiaoli; Urie, Bridget K; London, Cheryl A; Byrd, John C; Johnson, Amy J; Kisseberth, William C (2016. ) Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.PloS one, , 11 (7 ) ,e0159607 More Information

Browning, Rebekah L; Mo, Xiaokui; Muthusamy, Natarajan; Byrd, John C (2015. ) CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway.Oncotarget, , 6 (18 ) ,15931-9 More Information

Christian, Beth A; Poi, Ming; Jones, Jeffrey A; Porcu, Pierluigi; Maddocks, Kami; Flynn, Joseph M; Benson, Don M; Phelps, Mitch A; Wei, Lai; Byrd, John C; Wegener, William A; Goldenberg, David M; Baiocchi, Robert A; Blum, Kristie A (2015. ) The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.British journal of haematology, , 169 (5 ) ,701-10 More Information

Awan, Farrukh T; Hillmen, Peter; Hellmann, Andrzej; Robak, Tadeusz; Hughes, Steven G; Trone, Denise; Shannon, Megan; Flinn, Ian W; Byrd, John C (2014. ) A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.British journal of haematology, , 167 (4 ) ,466-77 More Information

Rafiq, Sarwish; Butchar, Jonathan P; Cheney, Carolyn; Mo, Xiaokui; Trotta, Rossana; Caligiuri, Michael; Jarjoura, David; Tridandapani, Susheela; Muthusamy, Natarajan; Byrd, John C (2013. ) Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.Journal of immunology (Baltimore, Md. : 1950), , 190 (6 ) ,2702-11 More Information

Zelenetz, Andrew D; Wierda, William G; Abramson, Jeremy S; Advani, Ranjana H; Andreadis, C Babis; Bartlett, Nancy; Bellam, Naresh; Byrd, John C; Czuczman, Myron S; Fayad, Luis E; Glenn, Martha J; Gockerman, Jon P; Gordon, Leo I; Harris, Nancy Lee; Hoppe, Richard T; Horwitz, Steven M; Kelsey, Christopher R; Kim, Youn H; Krivacic, Susan; LaCasce, Ann S; Nademanee, Auayporn; Porcu, Pierluigi; Press, Oliver; Pro, Barbara; Reddy, Nishitha; Sokol, Lubomir; Swinnen, Lode; Tsien, Christina; Vose, Julie M; Yahalom, Joachim; Zafar, Nadeem; Dwyer, Mary A; Naganuma, Maoko (2013. ) Non-Hodgkin's lymphomas, version 1.2013.Journal of the National Comprehensive Cancer Network : JNCCN, , 11 (3 ) ,257-72; quiz 273 More Information

Ji, Jia; Mould, Diane R; Blum, Kristie A; Ruppert, Amy S; Poi, Ming; Zhao, Yuan; Johnson, Amy J; Byrd, John C; Grever, Michael R; Phelps, Mitch A (2013. ) A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Clinical cancer research : an official journal of the American Association for Cancer Research, , 19 (5 ) ,1269-80 More Information

Ni, Wenjun; Ji, Jia; Dai, Zunyan; Papp, Audrey; Johnson, Amy J; Ahn, Sunjoo; Farley, Katherine L; Lin, Thomas S; Dalton, James T; Li, Xiaobai; Jarjoura, David; Byrd, John C; Sadee, Wolfgang; Grever, Michael R; Phelps, Mitch A (2010. ) Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.PloS one, , 5 (11 ) ,e13792 More Information

Awan, Farrukh T; Lapalombella, Rosa; Trotta, Rossana; Butchar, Jonathan P; Yu, Bo; Benson, Don M; Roda, Julie M; Cheney, Carolyn; Mo, Xiaokui; Lehman, Amy; Jones, Jeffrey; Flynn, Joseph; Jarjoura, David; Desjarlais, John R; Tridandapani, Susheela; Caligiuri, Michael A; Muthusamy, Natarajan; Byrd, John C (2010. ) CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.Blood, , 115 (6 ) ,1204-13 More Information

Sanchez-Aguilera, A; Rattmann, I; Drew, D Z; Müller, L U W; Summey, V; Lucas, D M; Byrd, J C; Croce, C M; Gu, Y; Cancelas, J A; Johnston, P; Moritz, T; Williams, D A (2010. ) Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia.Leukemia, , 24 (1 ) ,97-104 More Information

Garzon, Ramiro; Liu, Shujun; Fabbri, Muller; Liu, Zhongfa; Heaphy, Catherine E A; Callegari, Elisa; Schwind, Sebastian; Pang, Jiuxia; Yu, Jianhua; Muthusamy, Natarajan; Havelange, Violaine; Volinia, Stefano; Blum, William; Rush, Laura J; Perrotti, Danilo; Andreeff, Michael; Bloomfield, Clara D; Byrd, John C; Chan, Kenneth; Wu, Lai-Chu; Croce, Carlo M; Marcucci, Guido (2009. ) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.Blood, , 113 (25 ) ,6411-8 More Information

Liu, Qing; Zhao, Xiaobin; Frissora, Frank; Ma, Yihui; Santhanam, Ramasamy; Jarjoura, David; Lehman, Amy; Perrotti, Danilo; Chen, Ching-Shih; Dalton, James T; Muthusamy, Natarajan; Byrd, John C (2008. ) FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.Blood, , 111 (1 ) ,275-84 More Information

Treon, Steven P.; Agus, David B.; Link, Brian; Rodrigues, Gilberto; Molina, Arturo; Lacy, Martha Q.; Fisher, David C.; Emmanouilides, Christos; Richards, Arthur I.; Clark, Bruce; Lucas, Marjorie S.; Schlossman, Robert; Schenkein, David; Lin, Boris; Kimby, Eva; Anderson, K. C.; Byrd, John C. (2001. ) CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Journal of immunotherapy : official journal of the Society for Biological Therapy, , 24 (3 ) ,272-279

Academic - MSB
231 Albert Sabin
Cincinnati  Ohio, 45267
Phone: 513-558-0858